Preview

Медицинский вестник Юга России

Расширенный поиск

Безопасность и эффективность применения Омализумаба при бронхиальной астме

https://doi.org/10.21886/2219-8075-2019-10-2-6-12

Полный текст:

Аннотация

В настоящем обзоре литературы рассмотрены вопросы эффективности и безопасности терапии омализумабом при бронхиальной астме при помощи рандомизированных исследований последних лет. Подробно освещены механизмы патогенеза бронхиальной астмы, эффективность приема препарата и его побочные эффекты. Рассмотрена эффективность приема омализумаба по следующим ключевым точкам исследований: необходимость применения ингаляционных глюкокортикостероидов, качество жизни пациентов и частота обострений. Системный поиск литературы проводился по базам данных Scopus, Web of Science, MedLine, elibrary и другим.

Об авторах

Е. А. Стрельцов
Медицинский университет Караганды
Казахстан

Стрельцов Евгений Александрович - внутренние болезни, врач-интерн



В. С. Демидов
Медицинский университет Караганды
Казахстан

Демидов Владислав Сергеевич - внутренние болезни, врач-интерн



Л. В. Цой
Медицинский университет Караганды
Казахстан

Цой Людмила Владимировна - внутренние болезни, врач-интерн



М. Э. Коровина
Медицинский университет Караганды
Казахстан

Коровина Мария Эдуардовна - внутренние болезни, врач-интерн



Н. М. Разыщикова
Медицинский университет Караганды
Казахстан

Разыщикова Надежда Максимовна - внутренние болезни, врач-интерн



А. Е. Каржауова
Медицинский университет Караганды
Казахстан
Каржауова Асель Есеткызы - внутренние болезни, врач-интерн


Список литературы

1. Kubo M. Innate and adaptive type 2 immunity in lung allergic inflammation. // Immunol Rev. - 2017. -V.278(1). - P.162172. doi: 10.1111/imr.12557

2. Nabih E.S., Kamel H.F., Kamel T.B. Association between CD14 polymorphism (-1145G/A) and childhood bronchial asthma. // Biochem Genet. - 2016. - V.54. - P.50-60. doi: 10.1007/s10528-015-9699-4

3. Dissanayake S., Jain M., Grothe B., Mciver T., Papi A. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. // Pulm Pharmacol Ther. - 2015. -V.35. - P.19-27. doi: 10.1016/j.pupt.2015.10.001

4. Crocker D.D. , Kinyota S., Dumitru G.G., Ligon C.B., Herman E.J., Ferdinands J.M. et all. Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthmamorbidity: a community guide systematic review. // Am JPrev Med. - 2011. - V.41(2 Suppl 1). - P.S5-32. doi: 10.1016/j.amepre.2011.05.012

5. CDC. Asthma: most recent asthma data. 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/asthma/most_recent_data.htm

6. Patel O., Syamlal G., Wood J., Dodd K.E., Mazurek J.M. Asthma Mortality Among Persons Aged 15-64 Years, by Industry and Occupation - United States, 1999-2016. // MMWR Morb Mortal Wkly Rep. - 2018. - V.67(2). - P.60-65. doi: 10.15585/mmwr.mm6702a2

7. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. // Allergy. - 2004. - V.59(5). - P.469-78.

8. Tsai M.K., Lin Y.C., Huang M.Y., Lee M.S., Kuo C.H., Kuo P.L. et all. The effects of asthma medications on reactive oxygen species production in human monocytes. // J Asthma. -2017. -V.55(4). - P.345-353. doi: 10.1080/02770903.2017.1339798

9. Kaiser S.V., Rodean J., Bekmezian A., Hall M., Shah S.S., Ma-hant S. et all. Pediatric Research in Inpatient Settings (PRIS) Network: Rising utilization of inpatient pediatric asthma pathways. // J Asthma. - 2017. - V.55(2). - P.196-207. doi: 10.1080/02770903.2017.1316392

10. Galli S.J. Mast cells and KIT as potential therapeutic targets in severe asthma. // N Engl J Med. - 2017. - V.376(20). - P.19831984. doi: 10.1056/NEJMe1702653.

11. Fahy J.V. Type 2 inflammation in asthma—present in most, absent in many. // Nat Rev Immunol. - 2015. - V.15. - P.5765. doi: 10.1038/nri3786

12. Endo Y., Iwamura C., Kuwahara M., Suzuki A., Sugaya K., Tumes D.J. et all. Eomesodermin controls interleukin-5 production in memory T helper 2 cells through inhibition of activity of the transcription factor GATA3. // Immunity. - 2011. - V.35(5). - P.733-45. doi: 10.1016/j.immu-ni.2011.08.017.

13. Nakayama T., Hirahara K., Onodera A., Endo Y., Hosoka-wa H., Shinoda K et all. Th2 cells in health and disease. // Annu Rev Immunol. - 2017. - V.35. - P.53-84. doi: 10.1146/annurev-immunol-051116-052350

14. Hess C., Kemper C. Complement-mediated regulation of metabolism and basic cellular processes. // Immunity. - 2016. -V.45(2). - P.240-54. doi: 10.1016/j.immuni.2016.08.003.

15. Platts-Mills T.A. The role of immunoglobulin E in allergy and asthma. // JRespir Crit Care Med. - 2001. - V.164(8 Pt 2). -P.S1-5.

16. Sutton B.J, Davies A.M. Structure and dynamics of IgE-re-ceptor interactions: FceRI and CD23/FceRII. // Immunol. Rev. - 2015. - V.268(1). - P.222-35. doi: 10.1111/imr.12340

17. Holgate S.T. New strategies with anti-IgE in allergic diseases. // World Allergy Organ. J. - 2014. - V.7(1). - P.17. doi: 10.1186/1939-4551-7-17

18. Schulman E.S. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. // Am J Respir Crit Care Med. -2001. - V.164. - P.S6-S11.

19. Pereira Santos M.C., Campos Melo A., Caetano A., Caiado J., Mendes A., Pereira Barbosa M. et all. Longitudinal study of the expression of FceRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with omalizumab. // Eur Ann Allergy Clin Immunol. - 2015. - V47. - P.38-40.

20. Lai T., Wang S., Xu Z., Zhang C., Zhao Y., Hu Y et all. Longterm efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. // Scientific Reports. - 2015. - V.5. - P.8191. doi: 10.1038/srep08191

21. Sattler C., Garcia G., Humbert M. Novel targets of omalizumab in asthma. // Curr Opin Pulm Med. - 2017. - V.23. - P.56-61.

22. Teach S.J., Gill M.A., Togias A., Sorkness C.A., Arbes S.J., Jr, Calatroni A et all. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. // J Allergy Clin Immunol. - 2015. -V.136. - P.1476-1485.

23. Hayashi H., Mitsui C., Nakatani E., Fukutomi Y., Kajiwara K., Watai K. et all. Omalizumab reduces cysteinyl leukotri-ene and 9a,11p-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. // J Allergy Clin Immunol. -2016. - V.137. - P.1585-1587.e4.

24. Fajt M.L., Wenzel S.E. Development of new therapies for severe asthma. // Allergy Asthma Immunol Res. - 2017. - V.9. -P.3-14.

25. Li J., Kang J., Wang C., Yang J., Wang L., Kottakis I. et all. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a Randomized Phase III Study. // Allergy Asthma Immunol Res. - 2016. - V.8. - P.319-328.

26. Kuprys-Lipinska I., Molinska K., Kuna P. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. // Pneumonol Alergol Pol. - 2016. - V.84. - P.232-243.

27. Carr T.F., Berdnikovs S., Simon H.U., Bochner B.S., Rosenwasser L.J. Eosinophilic bioactivities in severe asthma. // World Allergy Organ J. - 2016. - V.9. - P.21.

28. de Llano L.P., Vennera M.C., Alvarez F.J., Medina J.F., Bor-derias L., Pellicer Cet all. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. // J Asthma. - 2013. - V.50. - P.296-301.

29. Garcia G., Magnan A., Chiron R., Contin-Bordes C., Berger P., Taille C. et all. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. // Chest. - 2013. - V.144. - P.411419.

30. Pillai P., Chan Y.C., Wu S.Y., Ohm-Laursen L., Thomas C., Durham S.R. et all. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. // Eur Respir J. - 2016. - V.48. - P.1593-1601.

31. Chen H.C., Huang C.D., Chang E., Kuo H.P. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. // BMC Pulmonary Medicine. -2016. - V.16. - P.3. doi: 10.1186/s12890-015-0156-2

32. Niven R.M., Saralaya D., Chaudhuri R., Masoli M., Clifton I., Mansur A.H. et all. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). // BMJ Open. - 2016. - V.6(8). - P.e011857. doi: 10.1136/bmjopen-2016-011857

33. Donald D.W. Asthma and Therapeutics: Recombinant Therapies in Asthma. // Allergy Asthma Clin Immunol. -2005. - V.1(1). - P.34-41. doi: 10.1186/1710-1492-1-1-34

34. Scichilone N., Ventura M.T., Bonini M., Braido F., Bucca C., Caminati M. et all. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. // Clin Mol Allergy. - 2015. - V.13(1). - P.7. doi: 10.1186/s12948-015-0016-x

35. Sposato B., Scalese M., Latorre M., Scichilone N., Matucci A., Milanese M. et all. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. // Respir Med. -2016. - V.119. - P.141-149. doi: 10.1016/j.rmed.2016.09.005

36. Odajima H., Ebisawa M., Nagakura T., Fujisawa T., Akasawa A., Ito K. et all. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. // Allergol Int. - 2017. - V66(1). -P.106-115. doi: 10.1016/j.alit.2016.06.004

37. Al-Ahmad M., Arifhodzic N., Nurkic J., Maher A., Rodriguez-Bouza T., Al-Ahmed N. et all. “Real-life” Efficacy and Safety Aspects of Four-year Omalizumab Treatment for Asthma. // Med Princ Pract. - 2018. doi: 10.1159/000487482

38. Foroughi S., Foster B., Kim N., Bernardino L.B., Scott L.M., Metcalfe D.D. et all. (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. // J Allergy Clin Immunol. - 2007. - V.120(3). - P.594-601.

39. Di Bona D., Fiorino I., Taurino M., Frisenda F., Minenna E., Pasculli C. et all. Long-term «real-life» safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. // Respir Med. - 2017. - V.130. - P.55-60. doi: 10.1016/j.rmed.2017.07.013

40. Simpson C.R., Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. // J R Soc Med. - 2010. - V.103. - P.98-106. doi:10.1258/jrsm.2009.090348

41. Odajima H., Ebisawa M., Nagakura T., Fujisawa T., Akasawa A., Ito K. et all. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. // Allergol Int. - 2015. - V64(4). - P.364-70. doi: 10.1016/j.alit.2015.05.006.

42. Iribarren C., Rahmaoui A., Long A.A., Szefler S.J., Bradley M.S., Carrigan G. et all. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. // J Allergy Clin Immunol. - 2017. - V.139(5). -P.1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038.

43. Li J., Kang J., Wang C., Yang J., Wang L., Kottakis I. et all. Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study. // Allergy Asthma Immunol Res. -2016. - V.8(4). - P.319-28. doi: 10.4168/aair.2016.8.4.319

44. Hide M., Igarashi A., Yagami A., Chinuki Y., Inomata N., Fu-kunaga A. et all. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. // Allergol Int. - 2017. - P.S1323-8930(17)30154-5. doi: 10.1016/j.alit.2017.10.001


Для цитирования:


Стрельцов Е.А., Демидов В.С., Цой Л.В., Коровина М.Э., Разыщикова Н.М., Каржауова А.Е. Безопасность и эффективность применения Омализумаба при бронхиальной астме. Медицинский вестник Юга России. 2019;10(2):6-12. https://doi.org/10.21886/2219-8075-2019-10-2-6-12

For citation:


Strel’tsov E.A., Demidov V.S., Tsoy L.V., Korovina M.E., Razyschikova N.M., Karzhauova А.E. Safety and efficiency of using Omaulizumab in bronchial asthma. Medical Herald of the South of Russia. 2019;10(2):6-12. (In Russ.) https://doi.org/10.21886/2219-8075-2019-10-2-6-12

Просмотров: 27


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2219-8075 (Print)
ISSN 2618-7876 (Online)